Gene therapy for hemophilia? No

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 8, 2004, Pages 1236-1237

  Giangrande, Paul L F ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; LENTIVIRUS VECTOR; PARVOVIRUS VECTOR; RETROVIRUS VECTOR;

BONE MARROW TRANSPLANTATION; CANCER; CARCINOGENESIS; CELL BASED GENE THERAPY; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; CONCENTRATION RESPONSE; CONSERVATIVE TREATMENT; CYSTIC FIBROSIS; DEATH; DIET THERAPY; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DNA VECTOR; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; ENZYME DEFICIENCY; GENE DELETION; GENE EXPRESSION; GENE INSERTION; GENE INTERACTION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSCRIPTION; HEMATOPOIETIC STEM CELL; HEMOPHILIA; HUMAN; IMMUNOGENICITY; INFLAMMATION; INFORMED CONSENT; LEUKEMIA; LIVER DYSFUNCTION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MEDICAL ETHICS; MULTIPLE ORGAN FAILURE; MUSCULAR DYSTROPHY; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTO ONCOGENE; RESPIRATORY DISTRESS; SHORT COURSE THERAPY; SPERM; T LYMPHOCYTE ACTIVATION; THALASSEMIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; VIRAL GENE DELIVERY SYSTEM;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

BIOETHICS; CLINICAL TRIALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMOPHILIA A; HUMANS; MALE; RISK; TRANSGENES;

EID: 13244269820     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00869.x     Document Type: Note

References (15)

1. Lucarelli G, Weatherall DJ. For debate: bone marrow transplantation for thalassaemia. Br J Haematol 1991; 78: 300-3.
2. Carmen IH. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001; 3: 425-8.
3. Assessment of adenoviral vector safety and toxicity: report of the National Institutes of Health Recombinant DNA Advisory Committee. Human Gene Ther 2002; 13: 3-13.
4. Mannucci PM. Hemophilia: treatment options in the twenty-first century. J Thromb Haemost 2003; 1: 1349-55.
5. Miller DG, Rutledge EA, Russell DW. Chromosomal effects of adenoassociated virus vector integration. Nat Genet 2002; 30: 147-8.
6. Buckley RH. Gene therapy for SCID-a complication after remarkable progress. Lancet 2002; 360: 1185-6.
7. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-9.
8. Brown DB, Lillicrap D. Dangerous liaisons: the role of 'danger' signals in the immune response to gene therapy. Blood 2002; 100: 1133-40.
9. Matzinger P. The danger model: a renewed sense of self. Science 2002; 296: 301-5.
10. Brown BD, Shi CX, Rawle FEM, Tinlin S, McKinven A, Hough C, Graham FL, Lillicrap, D. Factors influencing therapeutic efficacy and host immune response to helper-dependent adenoviral gene therapy in hemophilia A mice. J Thromb Haemost 2004; 2: 111-8.
11. Kay M, High K, Glader B, Manno CS, Hutchinson S, Dake M, Razavi M, Kaye R, Arruda VR, Herzog R, McClelland A, Rustagi P, Johnson F, Rasko JEJ, Hoots K, Blatt P, Leonard DGB, Addya K, Konkle B, Chew A, Couto L. A phase I/II clinical trial for liver directed AAV mediated gene transfer for severe hemophilia B. Blood 2002; 100 (Abstract 426).
12. Arruda VR, Schuettrumpf J, Couto LB, Leonard D, Addya K, Liu JH, Somer J, Herzog RW, Kay MA, Glader B, Manno CS, Chew A, High KA. Assessing the risk of inadvertent germline transmission of vector DNA following intravascular delivery of rAAV vector. Blood 2002; 100 (Abstract 3425).
13. Dimichele D, Miller FG, Fins JJ. Gene therapy ethics and haemophilia: an inevitable therapeutic future? Haemophilia 2003; 9: 145-52.
14. United Kingdom Haemophilia Centre Doctors' Organisation Working Party. Gene therapy trials in the UK: is haemophilia a suitable'model'? Clin Med 2004; 4: 54-6.
15. King NMP. Rewriting the 'points to consider': the ethical impact of guidance document language. Hum Gene Ther 1999; 10: 133-9.